A Phase 3 interventional study of Levetiracetam and Carbamazepine in Epilepsy and Partial Seizures, sponsored by UCB Pharma SA. Completed at 28 sites in China. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one is the 5th largest by enrollment, is one of 3 that started in 2013, is one of 28 in phase 3, and was the 48th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 436 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma SA, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma SA is the lead sponsor of 28 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 1 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 15th largest by enrollment of the 116 interventional ones that give a count, is one of 4 that started in 2013, is one of 74 in phase 3, and was the 89th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate the non-inferiority of Levetiracetam (1000 mg/day) versus Carbamazepine Immediate-Release (400 mg/day) used as monotherapy for at least 6 months in a Chinese population with newly or recently diagnosed Epilepsy who are experiencing Partial-Onset Seizures (POS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Levetiracetam 1000 mg/day
Drug: Levetiracetam
Carbamazepine 400 mg/day
Drug: Carbamazepine
Immediate release film-coated tablets at strengths of 250 mg and 500 mg. * Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid) * Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid * Down-titration Period (Week 30 up to Week 33)
Also known as: Keppra
Immediate release tablets at a strength of 200 mg. * Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd) * Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid * Down-titration Period (Week 30 up to Week 33)
Also known as: Tegretol
Proportion of Subjects Remaining Seizure Free During the 6-months Evaluation Period
Time frame: 6-months Evaluation Period (From Week 4 to Week 30)
Proportion of Subjects Retained in the Study for the Duration of the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period
Time frame: From Week 1 to Week 30
Time to First Seizure or Discontinuation Due to an Adverse Event (AE) / Lack of Efficacy (LOE) During the Evaluation Period
Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.
Time frame: From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)
Time to First Seizure During the Evaluation Period
Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.
Time frame: From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)
Time to First Seizure During the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period From the First Dose of Study Drug
Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.
Time frame: From Randomization (Week 1) up to Evaluation Visit (Week 30)
This study started to enroll subjects in China in September 2013.
| Milestone | Levetiracetam | Carbamazepine-IR |
|---|---|---|
| Started | 220 | 216 |
| Completed | 93 | 125 |
| Not completed | 127 | 91 |
| Withdrew: Lack of efficacy | 94 | 41 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Lost to follow-up | 5 | 6 |
| Withdrew: Withdrawal by subject | 18 | 12 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Ae, serious fatal | 1 | 0 |
| Withdrew: Ae, non-serious non-fatal | 5 | 22 |
| Withdrew: Sae, non-fatal | 1 | 4 |
| Withdrew: Non-compliant with study procedures | 1 | 0 |
| Withdrew: Non-compliant patient | 1 | 1 |
| Withdrew: Subject did not follow instructions | 0 | 2 |
| percentage of subjects | Levetiracetam (Per Protocol Set) | Carbamazepine-IR (Per Protocol Set) |
|---|---|---|
| Proportion of Subjects Remaining Seizure Free During the 6-months Evaluation Period | 47.3 | 68.4 |
| percentage of subjects | Levetiracetam (Per Protocol Set) | Carbamazepine-IR (Per Protocol Set) |
|---|---|---|
| Proportion of Subjects Retained in the Study for the Duration of the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period | 48.4 | 70.2 |
Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.
| events | Levetiracetam (Per Protocol Set) | Carbamazepine-IR (Per Protocol Set) |
|---|---|---|
| Time to First Seizure or Discontinuation Due to an Adverse Event (AE) / Lack of Efficacy (LOE) During the Evaluation Period | 88 | 45 |
Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.
| events | Levetiracetam (Per Protocol Set) | Carbamazepine-IR (Per Protocol Set) |
|---|---|---|
| Time to First Seizure During the Evaluation Period | 87 | 39 |
Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.
| events | Levetiracetam (Per Protocol Set) | Carbamazepine-IR (Per Protocol Set) |
|---|---|---|
| Time to First Seizure During the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period From the First Dose of Study Drug | 97 | 57 |
Collected over Adverse Events (AEs) were collected from Visit 1 (Week 0) until Safety Follow Up Visit (Week 35).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam (Safety Set) | — | 9/218 (4.1%) | 92/218 (42.2%) |
| Carbamazepine-IR (Safety Set) | — | 11/215 (5.1%) | 93/215 (43.3%) |
| Event | Levetiracetam (Safety Set) | Carbamazepine-IR (Safety Set) |
|---|---|---|
| Abortion inducedSurgical and medical procedures | 1/218 | 2/215 |
| Status epilepticusNervous system disorders | 2/218 | 1/215 |
| Thrombocytopenic purpuraBlood and lymphatic system disorders | 0/218 | 1/215 |
| Peripheral swellingGeneral disorders | 0/218 | 1/215 |
| Lung infectionInfections and infestations | 0/218 | 1/215 |
| Hand fractureInjury, poisoning and procedural complications | 1/218 | 1/215 |
| OverdoseInjury, poisoning and procedural complications | 0/218 | 1/215 |
| Patella fractureInjury, poisoning and procedural complications | 0/218 | 1/215 |
| Rib FractureInjury, poisoning and procedural complications | 0/218 | 1/215 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/218 | 1/215 |
| Event | Levetiracetam (Safety Set) | Carbamazepine-IR (Safety Set) |
|---|---|---|
| NasopharyngitisInfections and infestations | 40/218 | 32/215 |
| DizzinessNervous system disorders | 33/218 | 18/215 |
| SomnolenceNervous system disorders | 20/218 | 7/215 |
| HeadacheNervous system disorders | 19/218 | 16/215 |
| Upper respiratory tract infectionInfections and infestations | 12/218 | 16/215 |
| Blood cholesterol increasedInvestigations | 6/218 | 11/215 |
| Gamma-glutamyltransferase increasedInvestigations | 2/218 | 11/215 |
| White blood cell count decreasedInvestigations | 1/218 | 11/215 |
| Urinary tract infectionInfections and infestations | 11/218 | 5/215 |
The Baseline Characteristics refers to the Safety Set (SS) which consists of all subjects who were randomized and received at least 1 dose of trial medication.
| Age, Categorical(Participants) | Levetiracetam (Safety Set) | Carbamazepine-IR (Safety Set) | Total Title |
|---|---|---|---|
| <=18 years | 20 | 22 | 42 |
| Between 18 and 65 years | 184 | 186 | 370 |
| >=65 years | 14 | 7 | 21 |
| Age, Continuous(years) | Levetiracetam (Safety Set) | Carbamazepine-IR (Safety Set) | Total Title |
|---|---|---|---|
| mean (standard deviation) | 37.8 ± 16.2 | 33.3 ± 14.3 | 35.6 ± 15.4 |
| Sex: Female, Male(Participants) | Levetiracetam (Safety Set) | Carbamazepine-IR (Safety Set) | Total Title |
|---|---|---|---|
| Female | 106 | 94 | 200 |
| Male | 112 | 121 | 233 |
The record gives a start of Sep 2013, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam